Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Abbott Laboratories (NYSE:ABT)

37.91
Delayed Data
As of Jun 24
 -1.72 / -4.34%
Today’s Change
36.00
Today|||52-Week Range
51.74
-15.59%
Year-to-Date
'Mad Money' Lightning Round: Intel Is Just Treading Water
Jun 23 / TheStreet.com - Paid Partner Content
Shire Buys Global Rights to Pfizer's Gastrointestinal Drug
Jun 15 / Zacks.com - Paid Partner Content
Abbott Laboratories (ABT) Marked As A Barbarian At The Gate
Jun 22 / TheStreet.com - Paid Partner Content
Novo Nordisk (NVO) Reports Positive Trial Results on Victoza
Jun 15 / Zacks.com - Paid Partner Content
Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug
Jun 20 / Zacks.com - Paid Partner Content
Shire Gets Breakthrough Status for Rare Disease Candidates
Jun 14 / Zacks.com - Paid Partner Content
Opinions Differ on Abbott Deal to Acquire St. Jude's Medical
Jun 18 / GuruFocus News - Paid Partner Content
Abbott Labs (ABT) Reports Positive Data on FreeStyle Libre
Jun 14 / Zacks.com - Paid Partner Content
Abbott Laboratories (ABT) Is in Oversold Territory: What's Next?
Jun 17 / Zacks.com - Paid Partner Content
George Soros' Worst-Performing Stocks of 2016 So Far
Jun 11 / MotleyFool.com - Paid Partner Content
Aegerion, QLT Ink Merger Deal to Form Novelion Therapeutics
Jun 17 / Zacks.com - Paid Partner Content